Evolus Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Newport beach, calif.--(business wire)--evolus, inc. (nasdaq: eols), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on tuesday, may 7, 2024, after the u.s. financial markets close. evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. et that same day. a question-and-answer session will follow management's remarks. to parti.

Newport beach, calif.--(business wire)--evolus, inc. (nasdaq: eols), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the aesthetic surgery journal has published the safety and duration of effect results from the phase 2 study of 40u jeuveau® (prabotulinumtoxina-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. the “extra-strength” glabellar line study is a multicenter, double-blind, randomized,.

Newport beach, calif.--(business wire)--evolus, inc. (nasdaq: eols), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 9,651 shares of evolus and an aggregate of 20,971 restricted stock units (rsus) of the company's common stock to 10 newly hired non-executive employees of the company. the awards were approved by the compensation committee of the company's board of.

Newport beach, calif.--(business wire)--evolus, inc. (nasdaq: eols), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in april: event: the 23rd annual needham virtual healthcare conference date: tuesday, april 9th, 2024 time: 9:30 – 10:10 am et the fireside chat can be accessed on the investor relations page of the evolus website here. a replay of the webcast will b.

Newport beach, calif.--(business wire)--evolus, inc. (nasdaq: eols) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on friday, march 8, 2024, before underwriting discounts and commissions. the gross proceeds from the offering to evolus are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and offering expense.

Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To parti.

Evolus, a global performance beauty company, raised $60m in its IPO in 2018. Its first and only commercial product, Jeuveau, is an injectable botulinum toxin Type A product that has been approved in the US and most European territories. Evolus has settled a lawsuit with AbbVie and is focused on taking on Botox in the commercial markets.

Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.

The consensus price target hints at a 63.2% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Evolus, Inc. (NASDAQ:EOLS ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Louise Chen - Cantor Fitzgerald Navann Ty - BNP Paribas Serge Belanger - Needham & Company Uy Ear - Mizuho Securities Douglas Tsao - H.C. Wainwright Operator Good afternoon, everyone, and thank you for standing by.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--To participate in the conference call, dial (877) 407-6184 or (201) 389-0877 or join the webcast on the Investor Relations page of the Evolus website.

The consensus price target hints at a 133.9% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Evolus, Inc. (EOLS) Q3 2023 Earnings Call Transcript

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November.   Event:   Stifel 2023 Healthcare Conference   Date:   Wednesday, November 15, 2023   Time:   11:30 AM ET           Event:   6th Annual Evercore ISI HealthCONx Conference   Date:   Tuesday, November 28, 2023   Time:.